Envoy Medical to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
03 April 2024 - 11:05PM
Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a
revolutionary hearing health company focused on fully implanted
hearing systems, today announced that Brent Lucas, Chief Executive
Officer, and David R. Wells, Chief Financial Officer, will present
a corporate overview at the LD Micro Invitational XIV 2024.
The conference is being held on April 8 - 9, 2024 at the Sofitel
Hotel in New York City.
Presentation Date:
Tuesday, April 9, 2024
Time:
2:30pm
ET (Track 3 – St. Germain III)
Register below to view the
presentation:https://ldinv14.sequireevents.com/
Mr. Lucas and Mr. Wells will be holding one-on-one meetings with
registered investors and analysts at the conference to discuss
recent events and updates on clinical trials. To schedule a
one-on-one meeting, please contact Dean Summers at LD Micro
(dean@ldmicro.com) or CORE IR
(investorrelations@envoymedical.com).
About the Fully Implanted Acclaim® Cochlear
Implant
We believe the fully implanted Acclaim Cochlear Implant
(“Acclaim CI”) will be a first-of-its-kind fully implanted cochlear
implant. Envoy Medical’s fully implanted technology includes a
sensor designed to leverage the natural anatomy of the ear instead
of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound
sensorineural hearing loss that is not adequately addressed by
hearing aids. The Acclaim CI is expected to be indicated for adults
who have been deemed adequate candidates by a qualified
physician.
The Acclaim Cochlear Implant received the Breakthrough Device
Designation from the U.S. Food and Drug Administration (FDA) in
2019. We believe the Acclaim CI was the first hearing-focused
device to receive Breakthrough Device Designation.
CAUTION The fully implanted Acclaim Cochlear Implant is
an investigational device. Limited by United States law to
investigational use.
About the Esteem® Fully Implanted Active Middle Ear
Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI)
is the only FDA-approved, fully implanted* hearing device for
adults diagnosed with moderate to severe sensorineural hearing loss
allowing for 24/7 hearing capability using the ear’s natural
anatomy. The Esteem FI-AMEI hearing implant is invisible and
requires no externally worn components and nothing is placed in the
ear canal for it to function. Unlike hearing aids, you never
put it on or take it off. You can’t lose it. You don’t clean it.
The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer
is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found
at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may
be obtained free of charge at the SEC’s website
at www.sec.gov.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-Looking
statements may be identified by the use of words such as
“estimate,” “plan,” “project,” “forecast,” “intend,” “will,”
“expect,” “anticipate,” “believe,” “seek,” “target” or other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters, but the
absence of these words does not mean that a statement is not
forward-looking. Such statements may include, but are not limited
to, statements regarding the expectations of Envoy Medical
concerning the outlook for its business, productivity, plans and
goals for future operational improvements and capital investments,
the availability and benefits of future funding, the Acclaim CI
being the first to market fully implanted cochlear implant, the
impact of proposed legislation on the hearing health market,
reimbursement for the Esteem FI-AMEI device, and the Envoy Medical
business, and future market conditions or economic performance, as
well as any information concerning possible or assumed future
operations of Envoy Medical. The forward-looking statements
contained in this press release reflect Envoy Medical’s current
views about future events and are subject to numerous known and
unknown risks, uncertainties, assumptions and changes in
circumstances that may cause its actual results to differ
significantly from those expressed in any forward-looking
statement. Envoy Medical does not guarantee that the transactions
and events described will happen as described (or that they will
happen at all). These forward-looking statements are subject to a
number of risks and uncertainties, including, but not limited to
changes in the market price of shares of Envoy Medical’s Class A
Common Stock; Envoy Medical’s success in retaining or recruiting,
or changes required in, its officers, key employees or directors;
unpredictability in the medical device industry, the regulatory
process to approve medical devices, and the clinical development
process of Envoy Medical products; competition in the medical
device industry, and the failure to introduce new products and
services in a timely manner or at competitive prices to compete
successfully against competitors; disruptions in relationships with
Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own
production capabilities for some of the key components and
materials of its products; changes in the need for capital and the
availability of financing and capital to fund these needs; changes
in interest rates or rates of inflation; legal, regulatory and
other proceedings could be costly and time-consuming to defend;
changes in applicable laws or regulations, or the application
thereof on Envoy Medical; a loss of any of Envoy Medical’s key
intellectual property rights or failure to adequately protect
intellectual property rights; the effects of catastrophic events,
including war, terrorism and other international conflicts; and
other risks and uncertainties set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward Looking
Statements” in the Registration Statement on Form S-4 (File
No. 333-271920) filed by Envoy Medical (then known as Anzu Special
Acquisition Corp I), and in other reports Envoy Medical files
with, the SEC. If any of these risks materialize or Envoy Medical’s
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. While
forward-looking statements reflect Envoy Medical’s good faith
beliefs, they are not guarantees of future performance. Envoy
Medical disclaims any obligation to publicly update or revise any
forward-looking statement to reflect changes in underlying
assumptions or factors, new information, data or methods, future
events or other changes after the date of this press release,
except as required by applicable law. You should not place undue
reliance on any forward-looking statements, which are based only on
information currently available to Envoy Medical.
###
Investor Contact: CORE IR 516-222-2560
investorrelations@envoymedical.com
Envoy Medical (NASDAQ:COCH)
Historical Stock Chart
From Apr 2024 to May 2024
Envoy Medical (NASDAQ:COCH)
Historical Stock Chart
From May 2023 to May 2024